Prostatype Genomics AB Cash Flow Reinvestment Rate
Latest as of June 2020:
0.06x
Prostatype Genomics AB cash flow reinvestment rate. Prostatype Genomics AB (PROGEN) has a Cash Flow Reinvestment Rate of 0.06x as of June 2020, reinvesting Skr361.71K (capex Skr361.71K ) from operating cash flow of Skr5.63 Million. Explore how well can Prostatype Genomics AB service its debt to assess how comfortably operating cash covers total debt obligations.
Reinvestment Rate
0.06x
(Capex + Investments) / Operating CF
Total Reinvested
Skr361.71K
Capex + Investments
Operating Cash Flow
Skr5.63 Million
SEK
Capital Expenditures
Skr361.71K
SEK
Prostatype Genomics AB Cash Flow Reinvestment Rate by Year (None–None)
Prostatype Genomics AB cash flow reinvestment rate by year from None to None. Year-by-year capital reinvestment analysis for Prostatype Genomics AB. For the full cash flow conversion analysis, see cash efficiency ratio of Prostatype Genomics AB.
| Year | Reinvestment Rate | Total Reinvested (SEK) | Operating CF | Capex | YoY Change |
|---|
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow